Douglas E. Williams - 31 Mar 2025 Form 4 Insider Report for Climb Bio, Inc. (CLYM)

Reporting relationship: Director
Issuer ticker: CLYM
Reported as of: 31 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Apr 2025, 16:23:03 UTC
Prior SEC filing: 19 Mar 2025
Next SEC filing: 05 Jun 2025
Source filing: View source filing
Reporting owner signature: Emily Pimblett, as Attorney-in-Fact

Key filing fact

Douglas E. Williams filed Form 4 for Climb Bio, Inc. (CLYM) on 01 Apr 2025.

Key facts

This page summarizes Douglas E. Williams's Form 4 filing for Climb Bio, Inc. (CLYM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Apr 2025, 16:23.

Change

Previous filing in this sequence was filed on 19 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLYM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +78,873
Change %
Price: $0.000000
Shares after: 78,873
Date: 31 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 78,873
Exercise price: $1.22
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying the option vest in equal monthly installments from November 8, 2024 (the "Vesting Commencement Date") until the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.